Romidepsin (FK228, Depsipeptide)

For research use only. Not for use in humans.

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。Romidepsin (FK228/depsipeptide) 在神经母细胞瘤肿瘤细胞中可控制生长并诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 13415.22 现货
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Romidepsin (FK228, Depsipeptide)发表文献112篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。Romidepsin (FK228/depsipeptide) 在神经母细胞瘤肿瘤细胞中可控制生长并诱导凋亡。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX3xfZRpOi53LUG1JI5O NYH4NY56PzJiaB?= NV2xcFNGcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NXe2NHpbOjV5OUC5NFc>
U2932  NV3mUYVJS2WubDDWbYFjcWyrdImgRZN{[Xl? M2\oZVIvPS1zNTDuUS=> MnfWO|IhcA>? MVnpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MVuyOVc6ODlyNx?=
OCI-LY7 NYmzUJRHS2WubDDWbYFjcWyrdImgRZN{[Xl? NVvnOIpxOi53LUG1JI5O NYnDOGZzPzJiaB?= MX;pcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh M{XjdVI2PzlyOUC3
Farage NYPDb25ZS2WubDDWbYFjcWyrdImgRZN{[Xl? MX:yMlUuOTVibl2= NU\nTlVuPzJiaB?= MlHYbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NGnKSogzPTd7MEmwOy=>
LY7/EBV MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEPheZQzNjVvMUWgcm0> NIHKfIw4OiCq NIXqO5pqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MlHqNlU4QTB7MEe=
U2932/EBV NV7yOZFlS2WubDDWbYFjcWyrdImgRZN{[Xl? MoLjNk42NTF3IH7N MnT0O|IhcA>? MYDpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mni1NlU4QTB7MEe=
HCT116 NFvUOmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[zOU02ODByIH7N MYSyOEBp MlXDSG1UVw>? NX7vVVJQcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MU[yOVQ6OjVzNR?=
ACH-2 M3jBVGZ2dmO2aX;uJGF{e2G7 MnrENU06KG6P Mo[0NlQhcA>? MlPZbY5lfWOnczDITXYuOSCHbo[g[ZhxemW|c3nvci=> M2nxTFI2OTR7NE[3
MCF-10A NES0WVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe2NGhnUUN3ME2wMlE4yrFyLkCxJI5O MlHSNlQ6PTR6NU[=
MCF-7 NVriO4t7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVixVJc4UUN3ME2xMlExyrFyLkKwJI5O MUGyOFk2PDh3Nh?=
SK-BR-3 NYHGfHVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonoTWM2OD1zLkCwxtExNjN3IH7N NIO5bHkzPDl3NEi1Oi=>
MDA-MB-231 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjGTWM2OD1yLk[4xtExNjF2IH7N NGj0TmczPDl3NEi1Oi=>
PC3 NYKyb2xpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPTTWM2OD1zLk[1xtExNjN3IH7N M3frW|I1QTV2OEW2
HCT116 NXXZfJZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW1TWM2OD1zLkCwxtExNjByIH7N NVfrOm1FOjR7NUS4OVY>
HCT116-p21-/- NV;u[Jl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[4d5dKSzVyPUGuNlbDuTBwM{egcm0> M3TGO|I1QTV2OEW2
S1 NYjiOmo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTYTWM2OD15Lk[3xtExNjJ7IH7N M1TWWFI1QTV2OEW2
SW620 NEPmeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;pU5ZmUUN3ME2wMlk{yrFyLkK5JI5O MVGyOFk2PDh3Nh?=
LOX-IMVI NHzHTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXDTWM2OD1yLki3xtExNjB|IH7N MkL4NlQ6PTR6NU[=
UACC-62 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHDVG9UUUN3ME2wMlU3yrFyLkG2JI5O NGPjS4ozPDl3NEi1Oi=>
MDA-MB-435 NYXVb2lzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXKXHN{UUN3ME2wMlkxyrFyLkC2JI5O NUXTXpdzOjR7NUS4OVY>
SF-295 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfWfG9sUUN3ME2wMlg5yrFyLkG1JI5O NVixdoFHOjR7NUS4OVY>
A549 NILSeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrSXWxHUUN3ME2xMlI3yrFyLkK0JI5O NW\YNJdlOjR7NUS4OVY>
H460 NHnzc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTJwNUlCtVAvQDBibl2= MkGyNlQ6PTR6NU[=
EKVX M4\o[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDBXmdKSzVyPUGuN|PDuTBwM{Sgcm0> M3:0WFI1QTV2OEW2
H146 NVS5SVNiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMkNCtVAvODdibl2= NYHqOGtNOjR7NUS4OVY>
H526 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwMUZCtVAvODNibl2= NIPVPZAzPDl3NEi1Oi=>
HuT-78 M4HOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHWNpRKSzVyPUGuO|PDuTBwNESgcm0> NV[2UWV7OjR7NUS4OVY>
HA NUm4cFY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXyRYkxNjZ{NT2xNI5O MVu0PEBp Mnr1bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> M4PTSFI1PzdzNUGw
MS-275 NHzPPYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXLeoRzOC54MkWtNVBvVQ>? M2jG[FQ5KGh? M1v4c4lv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NWXv[JkzOjR5N{G1NVA>
CD4 T NEPmdYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[0PEBp MnW1SWM2OD12LkZCtVEvOCCwTR?= NGPqTnQzPDd{MkS1OC=>
CD4 T M2nWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO0PEBp NYfWdpFPS0N3ME2xNFfDuTF{NjDuUS=> MoqzNlQ4OjJ2NUS=
CD4+ T MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzteYRkTUN3ME2zJI5O MWqyOFQ6PTFyNR?=
A549 NFn0b|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG2S2dJOTEkgKOxNFDDqG6P M3qxNVI1NzN4L{S4JIg> NEPBfJhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NX\B[lEyOjR2OEW3PVk>
JJN3 NU\MVGJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSyOE81QCCq M3PZcWVEPTB:MfMAjY5OQyB2OPMAjYg> MUmyOFA{ODF3MB?=
OPM-2 MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGyOE81QCCq MnvhSWM2OHN;MfMAjY5OQyB2OPMAjYg> NWiy[VdMOjRyM{CxOVA>
RPMI-8226 MonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuyOE81QCCq NVrtW4N{TUN3MIO9NU456oDLbl27JFQ56oDLaB?= MkHlNlQxOzBzNUC=
U266 M{HkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXeyOE81QCCq M4nGbGVEPTC|PUGw5qCKdk19IES45qCKcA>? NVr2[phyOjRyM{CxOVA>
CA46 MofyRZBweHSxc3nzJGF{e2G7 NUfvVFh1PiCq NG\JU5JqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NVviRWtmOjN7Nk[xOlQ>
DG75 M3WzWGFxd3C2b4Ppd{BCe3OjeR?= MXG2JIg> NH3NVHFqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? NXnGSYczOjN7Nk[xOlQ>
Ramos MVrBdI9xfG:|aYOgRZN{[Xl? M1LU[lYhcA>? M13kNolv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NXnxc5Y1OjN7Nk[xOlQ>
ST486 MoriRZBweHSxc3nzJGF{e2G7 NFvmSZU3KGh? NH7veldqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> NUC1U|ZzOjN7Nk[xOlQ>
HuT78 MVfBdI9xfG:|aYOgRZN{[Xl? NWX4[VJ5OS9zMD:xNFAhdk1? M3nX[VQ5KGh? NYLONWZkcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MXiyN|U{Ojd|Mh?=
DpVp35 MUfBdI9xfG:|aYOgRZN{[Xl? MVKxM|ExNzFyMDDuUS=> M3LDU|Q5KGh? NUDmSoptcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NFT4dVMzOzV|MkezNi=>
DpVp50 NH\kUnFCeG:ydH;zbZMhSXO|YYm= NFfER5MyNzFyL{GwNEBvVQ>? NX3nZ45JPDhiaB?= NGPZSHZqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NGLwelMzOzV|MkezNi=>
DpP75  MV3BdI9xfG:|aYOgRZN{[Xl? M2XLNVEwOTBxMUCwJI5O M1zBVFQ5KGh? NGHB[mtqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MlzJNlM2OzJ5M{K=
SKOV-3 NFnEPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYThfWtHOeLCk{Kwcm0> NXi2Z2E6PzJiaB?= NHHSUI9FVVOR NX;GO2lSemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MoPINlMxOTB|NEi=
Brca1 WT M33UZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXMNgKBmzJybl2= M3jzWFczKGh? M1[0XWROW09? M{\ZdJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NXuyeo5sOjNyMUCzOFg>
Brca1 Null MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7v[osy6oDVMkDuUS=> NUnE[mc5PzJiaB?= M4rYRWROW09? MWHy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NIG0dnYzOzBzMEO0PC=>
OVCAR-8  MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmxNgKBmzJybl2= MlTJO|IhcA>? M2jKWGROW09? NH3ST5Zz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NEf6WmozOzBzMEO0PC=>
NCI/ADR-RES NF7MRXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCx5qCUOjCwTR?= MYK3NkBp NWjkWGhbTE2VTx?= MVPy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> NIj4S4gzOzBzMEO0PC=>
HCT116 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{C2OFUhdk1vNUCg{txO MVOyOEBp NGK5ZoVFVVOR MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NHvHRmozOjl{NEm1PC=>
RKO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PRVFUhdk1vNUCg{txO NFPHZo0zPCCq NEe3fmxFVVOR NGWy[JdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? M4[3VlIzQTJ2OUW4
CO115 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nBO|Uhdk1vNUCg{txO MmfVNlQhcA>? NH7xepFFVVOR MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NVi5eoxnOjJ7MkS5OVg>
HFS NELGV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnvOUBvVQ>? MljYNlQwPDhxN{KgbC=> M3zZXolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MmLkNlIyODZ{OEK=
LNCaP MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPnSlQ2KG6P NEW5b2szPC92OD:3NkBp MXnpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 NYrMWHpmOjJzME[yPFI>
A549 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rOc|Uhdk1? MoX6NlQwPDhxN{KgbC=> MojmbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MVmyNlExPjJ6Mh?=
697  NGXvS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|Ux6oDLPfMAjVIvPcLibl2= MWCyNVU{QDJzNh?=
697-R MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzrW2hKSzVy4pEJQgKBkThwNtMgcm3DqA>? NHr3V3kzOTV|OEKxOi=>
HUT78 M2fodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXSfmRqUUN3ME2xJI5O NUm4bYNPOjFzOUi1OFU>
THJ-16T M4Ls[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;RbmtIOSCwTR?= MWWyOEBp NFTCbndqdmirYnn0d{Bk\WyuIHfyc5d1cA>? M2ixPFIxQDFyNU[4
HCT116 MoHXSpVv[3Srb36gRZN{[Xl? NE\SV5QzOCCwTR?= NXXOSINsQCCq NVPsZo9ydW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u M1e5PVIxPzN7NEW0
B104  MkLvSpVv[3Srb36gRZN{[Xl? MUiyJI5O NHvxbGgzPC92OD:3NkBp MUPpcoNz\WG|ZYOgeIhmKHO3cn\hZ4Uh\XiycnXzd4lwdiCxZjDDSFIxyqB? NG\EO|UzODZ6NkWwOS=>
HL-60  NIjld4ZEgXSxdH;4bYNqfHliQYPzZZk> MnrkNU02ODBibl2= MWiyOEBp M3;BV4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? Ml\oNlA3OjRzNkO=
HP100 NVzJS4psS3m2b4TvfIlkcXS7IFHzd4F6 MVOxMVUxOCCwTR?= NV;wd4VROjRiaB?= NXvRfYVwcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MmewNlA3OjRzNkO=
HL-60  MV3GeY5kfGmxbjDBd5NigQ>? NHL6coIyOCCwTR?= M1TOdlQwPi9zNjDo M1fCV4lv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= M17ENVIxPjJ2MU[z
HP100 M4T1[2Z2dmO2aX;uJGF{e2G7 M{fTfFExKG6P M{P1[lQwPi9zNjDo NIHzc4hqdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi= M3GyW|IxPjJ2MU[z
HL-60  MUDGeY5kfGmxbjDBd5NigQ>? MkL0NVAuPTByIH7N MnPNOEBp M3LuVYRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NIrwfHgzODZ{NEG2Ny=>
HP100 M2PZc2Z2dmO2aX;uJGF{e2G7 NFv6OoQyOC13MECgcm0> NXzkfZBzPCCq NXHZcnhn\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg MkDzNlA3OjRzNkO=
11z M{fYNmtqdmG|ZTDBd5NigQ>? NGn2d5c{NTFyMDDuUS=> NELlPJdz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NHiyPXYzODZyNUG0OC=>
SKOV-3 NG\uVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTXOE85NzF4IH7N NHHRSXo1QCCq MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NGfmcHUzODRyNEW2OC=>
OVCAR-3 NYDPe4plT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVW0M|gwOTZibl2= MmfJOFghcA>? NWqxd5dxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? M4jqPVIxPDB2NU[0
HBL-2 NFXkVYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTwNk0yOCCwTR?= NF;CSG4zPCCq NY\hdY5JUUN3ME20MlMhdk1? NGPlOG8zODB4OEC4NC=>
Jeko-1 MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSxNk02OCCwTR?= Mny1NlQhcA>? NIP2WIdKSzVyPUGxJI5O M2n3XFIxODZ6MEiw
Granta-519 NWfsNnNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPpOU01OCCwTR?= MYCyOEBp Mke1TWM2OD13OD61JI5O M4naN|IxODZ6MEiw
L1236 MlnVR5l1d3SxeHnjbZR6KEG|c3H5 NUPrZZh4OSCwTT2xNFAh|ryP NVTNT5RYPDhiaB?= NIO1cllGSzVyPUCuNFch|ryP MXqxPVI{OzR5MB?=
L428 MWjDfZRwfG:6aXPpeJkhSXO|YYm= NVTC[XNvOSCwTT2xNFAh|ryP NX\kSlVwPDhiaB?= NHHseo5GSzVyPUCuOFMh|ryP MoPqNVkzOzN2N{C=
KM-H2 NIjpXWZEgXSxdH;4bYNqfHliQYPzZZk> MkTJNUBvVS1zMECg{txO M{S3elQ5KGh? MkflSWM2OD1yLkW4JO69VQ>? MUGxPVI{OzR5MB?=
L540Cy NXzGeXhoS3m2b4TvfIlkcXS7IFHzd4F6 M{jRSVEhdk1vMUCwJO69VQ>? MVW0PEBp Ml\USWM2OD1yLkG2JO69VQ>? NHXieZoyQTJ|M{S3NC=>
G401 NIPhdlJHfW6ldHnvckBCe3OjeR?= NUCybVBFOTBibl2= Mn;PNlQwPDhxN{KgbC=> NHfpe|NFVVOR M2SyPIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MlHQNVkzOjF3OE[=
STM91-01 M3OycWZ2dmO2aX;uJGF{e2G7 M13nZ|ExKG6P NF\3R4czPC92OD:3NkBp NHTYWGRFVVOR NF\jeGJqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NFPzSXUyQTJ{MUW4Oi=>
SJSC  MkLQSpVv[3Srb36gRZN{[Xl? Mn\aNVAhdk1? MWKyOE81QC95MjDo MX\EUXNQ MkjzbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u Mn[5NVkzOjF3OE[=
BT16  MY\GeY5kfGmxbjDBd5NigQ>? M1LxZlExKG6P NWTidWh7OjRxNEivO|IhcA>? MXzEUXNQ NIexT2ZqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NUe0RWxYOTl{MkG1PFY>
NCI-H1299 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTRwNtMxNE4zKG6pL33s NInofYkyQTF5OUi5NC=>
NCI-2882 NUS5doU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rocWlEPTB;MT62xtExNjB2IH7nM41t Mkn3NVkyPzl6OUC=
HCC95 M3\YfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[4fIlKSzVyPUKuOeKyOC5yNTDu[{9udA>? NHLVUGkyQTF5OUi5NC=>
NCI-H23 NFHoVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTNTWM2OD1{LkpCtVAvOiCwZz;tcC=> NEHHNWcyQTF5OUi5NC=>
NCI-H157 NEHzbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwNtMxNE4xOiCwZz;tcC=> M2m0TFE6OTd7OEmw
NCI-H460 M1zEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vHS2lEPTB;Mj6xxtExNjB5IH7nM41t NX73OXJHOTlzN{m4PVA>
NCI-H1975 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TuR2lEPTB;MT6zxtExNjB2IH7nM41t MXmxPVE4QTh7MB?=
NCI-H820 Mn21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LoTWlEPTB;Mj60xtExNjFibnevcYw> NE\EN4syQTF5OUi5NC=>
NCI-H1650 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnlNJVRUUN3ME20MlnDuTBwMzDu[{9udA>? NXPOSmNWOTlzN{m4PVA>
DTC1 M3;KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\KWGlEPTB;MD61NUBvVQ>? NFizd4cyQDV4NkK0Oi=>
KAO NVX2TYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPVSZFKSzVyPUCuPVEhdk1? NEf6NG0yQDV4NkK0Oi=>
SU-CCS-1 NIfOeotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;VSWlEPTB;MD64PUBvVQ>? NWnPcnU5OTh3Nk[yOFY>
SYO-1 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK0So9xUUN3ME2wMlY4KG6P MXexPFU3PjJ2Nh?=
FUJI MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHZN5N{UUN3ME2xMlMyKG6P MVyxPFU3PjJ2Nh?=
SKNMC NXrEPZR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMUegcm0> MnXqNVg2PjZ{NE[=
402-91 M3;FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmq5TWM2OD1zLkK2JI5O NF\SRpQyQDV4NkK0Oi=>
1765-92 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFwN{egcm0> NFjWUW8yQDV4NkK0Oi=>
JN-DSRCT-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFwMkWgcm0> MWWxPFU3PjJ2Nh?=
NMS-2PC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHybJd5UUN3ME2wMlgyKG6P MWSxPFU3PjJ2Nh?=
HL60 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofsTWM2OD1zLki2JI5O NGftcIgyQDV4NkK0Oi=>
A549 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3c2lEPTB;Mz6yOEBvVQ>? MnLaNVg2PjZ{NE[=
SW480 NXzK[JV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rMVWlEPTB;Mj62PUBvVQ>? MojPNVg2PjZ{NE[=
MCF7 M3T1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HlUWlEPTB;Mz61OUBvVQ>? MkPxNVg2PjZ{NE[=
PC-3 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXn0bZNrUUN3ME2yMlUyKG6P NGrQenEyQDV4NkK0Oi=>
MMRU NHjjTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCzTWM2OD1{LkW3JI5O NV[0ZW5jOTh3Nk[yOFY>
Hs68 NXn5d4ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFL2TZBKSzVyPU6xNEBvVQ>? NWP2TVJkOTh3Nk[yOFY>
hMSC-001F MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG5SYtKSzVyPU6xNEBvVQ>? MVmxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
- 合并
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
储存条件 粉状
溶于溶剂
别名 FR 901228, NSC 630176

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Active not recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID